⭐4.CAR-T（北京博仁医院CD7-CAR-T，Ⅱ期）—Ⅰ期数据显示完全缓解的有效性，可控的安全性 （Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial）⭐5. WU-CART-007（Wugen 的CD7-CAR-T，Ⅱ期）—公开的IND效果好，预计主要...
近日，一项聚焦自体CD7 CAR-T治疗儿童R/R T-ALL的研究“Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial”发表于Molecular Therapy（IF:12.4），初步探索和揭示无T细胞分选的自体CD7 CAR-T细胞的制备、以及其治疗r/r...
Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin Exp Immunol. 1994 Oct; 98 (1):163–168. [ PMC free article ] [ PubMed ]Kukel S, Reinhold U, Oltermann I, Kreysel HW. Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin ...
⭐4.CAR-T(北京博仁医院CD7-CAR-T,Ⅱ期)—Ⅰ期数据显示完全缓解的有效性,可控的安全性 (Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的I...
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) 5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
1# Jing Pan et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human， PhaseI Trial. （2021） Journal of Clinical Oncology.2# David T. Teachey and Stephen P. Hunger. Anti-CD7 CAR T cells for T-ALL: impressive early-stage ...
参考文献:Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management,doi:10.1158/1078-0432.CCR-20-1271; 识别微信二维码,添加生物制品圈小编,符合条件者即可加入生物制品微信群!
peripheral blood cells. This may be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 1...
T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially...